Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Karl Schwabe

Geriatric Medicine Havertown, PA Medical Doctor

NPI 1932101235 CMS profile 178157

301 W Chester Pike, Ste 201, Havertown, PA 19083

Open in the dashboard

General payments

$3,570

243 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Karl Schwabe of Havertown, PA is reported in the CMS Open Payments database as having received $3,570 across 243 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $77 3
2021 General $1,146 78
2020 General $939 61
2019 General $1,408 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karl Schwabe
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Karl Schwabe were reported at $0. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Karl Schwabe Geriatric Medicine median Middle half National median
2019 $1,408 $122 $40–$435 $163
2020 $939 $98 $25–$349 $114
2021 $1,146 $125 $34–$441 $132
2022 $77 $124 $36–$408 $149
2023 $0 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $0 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. GlaxoSmithKline, LLC. $462 34 payments
  2. Novo Nordisk Inc $416 32 payments
  3. Merck Sharp & Dohme Corporation $387 25 payments
  4. AbbVie, Inc. $369 30 payments
  5. Astellas Pharma US Inc $300 19 payments
  6. Novartis Pharmaceuticals Corporation $253 17 payments
  7. Pfizer Inc. $210 14 payments
  8. Amgen Inc. $183 11 payments
  9. Lilly USA, LLC $159 10 payments
  10. AstraZeneca Pharmaceuticals LP $127 8 payments
  11. Other $705 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,537 242 payments
  2. Education $33 1 payment
Products named General payments · program years 2019–2022
  1. JANUVIA $363 24 payments
  2. TRELEGY ELLIPTA $340 24 payments
  3. STEGLATRO $331 22 payments
  4. MYRBETRIQ $300 19 payments
  5. ASMANEX $288 18 payments
  6. Ozempic $257 19 payments
  7. ENTRESTO $253 17 payments
  8. VRAYLAR $232 17 payments
  9. BELSOMRA $204 11 payments
  10. Repatha $147 9 payments
  11. Other $2,902 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 180 drugs

Part D claims

11,104

Median for Geriatric Medicine: 2,306

Drug cost

$827,672

Median for Geriatric Medicine: $150,713

Branded share of claims

19.6%

Median for Geriatric Medicine: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 161 $152,396
Ozempic Semaglutide Brand 62 $86,953
Jardiance Empagliflozin Brand 75 $81,916
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 49 $53,684
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 12 $48,713
Xarelto Rivaroxaban Brand 38 $35,838
Mounjaro Tirzepatide Brand 28 $33,164
Januvia Sitagliptin Phosphate Brand 30 $27,512
Wegovy Semaglutide Brand 15 $19,401
Xtampza Er Oxycodone Myristate Brand 13 $15,864

The 10 drugs with the highest cost, of 180 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$82,193

Of which drugs: $16,643

Medicare patients

393

Average age 74

Services billed

2,152

186 women, 207 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Chronic kidney disease 27%
Diabetes 26%
Ischemic heart disease 25%
Depression 24%
Atrial fibrillation 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 118 119 $9,605
Pcv20 vaccine im 90677 Office 18 19 $5,513
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 11 11 $241

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

243 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record